pembrolizumab,nivolumab,ipilimumab
merck,bms
['cm-914', 'ipi +', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', ' ipi ', 'kn-564']
no benefit of ipi + nivo in the adjuvant setting for high risk rcc after nephrectomy (phase iii cm-914). striking data considering outcomes in kn-564 #esmo2022 #paris 
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ???? ????????? Avid traveller! ????